Siebeler et al. in Science Advances

Macrophages are central to the chronic inflammation in atherosclerotic plaques, but which epigenetic enzymes drive that inflammatory state?
Excited to share a new publication showing that the H3K9 demethylase KDM3A regulates type I interferon signaling in macrophages, thereby affecting atherosclerosis development
What we show:
• KDM3A potentiates interferon signaling in macrophages. Lose it, and H3K9me2/3 accumulates at KDM3A-bound regions while IFN-β production and ISG expression drop.
• Hematopoietic Kdm3a deficiency in Ldlr−/− mice gives smaller, less necrotic lesions with fewer neutrophils, explained by reduced macrophage CXCL1/CXCL2 secretion.
• Primary human macrophages behave the same upon KDM3A knockdown, and KDM3A-dependent signatures are overrepresented in IFN-activated inflammatory macrophages in human plaques.
• Modeling across Athero-Express carotid endarterectomy samples predicts a shift to more stable plaque phenotypes upon KDM3A inhibition.
Together this nominates KDM3A as a target for selectively dampening IFN-driven inflammation.
This was very much a team effort. Ricky Siebeler and
Hung-Jen (Oliver) Chen share first authorship, and the project was led by
Marten Hoeksema and
Menno de Winther. Other authors include
Tatyana Kuznetsova,
Annette Neele,
saskia van der velden, Marion Gijbels,
Guillermo R. Griffith, Cindy van Roomen,
Koen Prange,
Marieke Boshuizen,
Tom Seijkens,
Esther Lutgens,
Kaylin C. A. P. and
Michal Mokry.
Here is the link to the paper!


